NEW YORK (GenomeWeb News) – Cancer biotherapeutics developer H3 Biomedicine said today that it will partner with Sage Bionetworks to develop new software aimed at supporting its efforts to predict human responses to certain drugs.

Cambridge, Mass.-based H3 said the software will couple its genomic and drug data with Sage's predictive modeling and collaborative capabilities to identify and predict associations between specific genetic alterations and drug response.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: transcript patterns in drug-resistant cancer cells, function of high-altitude adaption gene, and more.

Monitoring gene expression changes could help sniff out athletes using performance-enhancing drugs, New Scientist says.

The University of Southern California lodges a cross-complaint in its legal dispute with the University of California, San Diego, over a large Alzheimer's disease project.

In PLOS this week: gene fusion in premature ovarian failure, population patterns in the Franciscana dolphin, and more.